Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 2, 2024Dermatology ReportsOpen Access

New and emerging therapies in cutaneous T-cell lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

GRGabriele RoccuzzoNMNicole MacagnoSGSilvia Giordano

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Roccuzzo et al. (2024) studied this question.

synapsesocial.com/papers/68e55ff7e2b3180350efc8ebhttps://doi.org/10.4081/dr.2024.10002
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer2016 · 446 citations
  2. 2Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity2017 · 283 citations
  3. 3A Phase <scp>II</scp> trial of Belinostat ( <scp>PXD</scp> 101) in patients with relapsed or refractory peripheral or cutaneous T‐cell lymphoma2014 · 193 citations
  4. 4Epigenetics of cutaneous T-cell lymphoma: biomarkers and therapeutic potentials2021 · 20 citations
  5. 5KIR3DL2 expression in cutaneous T-cell lymphomas: expanding the spectrum for KIR3DL2 targeting2017 · 46 citations